PPI-Induced Hyponatremia Mechanisms and Risks

Primary Mechanisms and Clinical Implications

Proton pump inhibitors (PPIs) can cause hyponatremia primarily through direct effects on renal water handling, leading to syndrome of inappropriate antidiuretic hormone secretion (SIADH), with the highest risk occurring during the first weeks of treatment, as reported by the American Association for the Study of Liver Diseases 1, 2, 3
PPIs increase gastric pH, which promotes intestinal microbial proliferation and dysbiosis, potentially contributing to systemic inflammation that may affect water homeostasis, according to the American Gastroenterological Association 1, 3
Impaired absorption of micronutrients due to PPI use may play a secondary role in electrolyte disturbances, as suggested by the National Institute of Diabetes and Digestive and Kidney Diseases 1, 3
In patients with cirrhosis, PPIs can exacerbate hyponatremia, which is already a risk factor for hepatic encephalopathy, creating a dangerous cycle, as noted by the American Association for the Study of Liver Diseases 1, 2, 3
Hyponatremia is the most common electrolyte abnormality in hospitalized patients, affecting a significant portion of the population, and can lead to severe complications if not properly managed, according to the American Academy of Pediatrics 4, 5
Monitoring of serum sodium is advisable when initiating PPI therapy, particularly in high-risk patients, as recommended by the American College of Gastroenterology 1, 3

The American Gastroenterological Association does not currently recommend routine screening for electrolyte abnormalities in all patients taking PPIs, but individual risk assessment is warranted 6